Introduction
Vitamin D deficiency is highly prevalent in children with chronic kidney disease (CKD) [1] [2] [3] [4] [5] [6] . The literature to date has focused on reduced renal production of circulating 1,25-dihydroxyvitamin D [1, 25(OH) 2 (CYP27B1) depends on this process [12, 13] . Changes in DBP concentrations secondary to glomerular and/or tubular damage in CKD could impair vitamin D transport and metabolism, and may influence the bioavailability of 25(OH)D to target tissues. A recent study in adult hemodialysis patients demonstrated that bioavailable 25(OH)D, the fraction that is not bound to DBP, was better correlated with measures of mineral metabolism than total 25(OH)D concentrations [7] . Risk factors for low bioavailable vitamin D concentrations have not been addressed in children with CKD. Vitamin D catabolism is an incompletely understood determinant of steady-state vitamin D metabolite concentrations in blood and tissue. CYP24A1 is the key enzyme involved in the catabolism of 25(OH)D and 1,25(OH) 2 D; 24,25-dihydroxyvitamin D [24, 25(OH) 2 D] is the main product of 25(OH)D catabolism. Like CYP27B1, CYP24A1 is expressed in most tissues and regulated by 1,25(OH) 2 D [14] [15] [16] . In vitro and animal studies have shown that renal CYP24A1 is suppressed by parathyroid hormone (PTH) [17] [18] [19] and induced by fibroblast growth factor-23 (FGF23) [20] [21] [22] . In a recent study in adults with CKD, lower estimated glomerular filtration rate (eGFR) was strongly associated with lower serum 24,25(OH) 2 D concentrations, and the negative correlation of PTH with 24,25(OH) 2 D was stronger than its correlations with 25(OH)D or 1,25(OH) 2 D [23] . Downregulation of CYP24A1 may represent an appropriate response to tissue-concentration 1,25(OH) 2 D deficiency [14] in CKD, and higher 24,25(OH) 2 D concentrations may provide a more accurate measure of functional vitamin D status.
We recently reported that hypoalbuminemia and glomerular disease, particularly FSGS, were independent risk factors for low 25(OH)D concentrations in pediatric CKD, adjusted for age, race, season, and CKD severity [4] . We hypothesized that the lower vitamin D concentrations in participants with glomerular disease were due to lower serum DBP concentrations. The objective of this study was to expand the assessment of vitamin D metabolism in this cohort to include measures of serum DBP, FGF23, and 24,25(OH) 2 D in order to identify correlates of bioavailable and free 25(OH)D concentrations and vitamin D catabolism in childhood CKD.
Methods

Study participants
This cross-sectional study of children and adolescents, aged 5-21 years, with CKD was conducted at the Children's Hospital of Philadelphia (CHOP) and Cincinnati Children's Hospital Medical Center (CCHMC), as previously described [4] . The original study reported total vitamin D concentrations in 182 participants with CKD compared to 276 healthy controls. The current study was limited to participants with the following underlying diseases: (1) congenital anomalies of the kidney/urinary tract (CAKUT), including aplastic/hypoplastic/dysplastic/cystic kidneys and obstructive uropathy; (2) glomerulonephritis (GN), including membranoproliferative GN, IgA nephropathy, Alport's syndrome, systemic lupus erythematosus, and Wegener's granulomatosis; (3) focal segmental glomerulosclerosis (FSGS). The 21 participants with other causes of CKD were not included in the present study. A total of 148 (92 %) patients had sufficient stored serum to measure FGF23 and DBP and estimate free and bioavailable 25(OH)D concentrations, while 140 (87 %) had sufficient stored serum to measure 24,25(OH) 2 D concentrations. As this was an ancillary study performed on stored serum, we did not have sufficient stored serum samples for the controls from our original study to measure DBP. There were no urine samples available to measure total protein excretion or DBP.
The Institutional Review Boards at CHOP and CCHMC approved the study protocol. Informed consent was obtained from participants ≥18 years of age, and assent along with parental consent from subjects <18 years, as appropriate.
Anthropometry and race
Height was measured with a stadiometer and weight with a digital scale. Height and body mass index (BMI, kg/m 2 ) Z-scores were calculated using national reference data [24] . Information on race was obtained by self-report and classified according to National Institutes of Health categories.
Laboratory measurements
Non-fasting blood samples were collected. Serum DBP was measured in duplicate [coefficient of variation (CV) <10 %] using an enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN). The inter-assay CV was 1.6-3.6 %, and recovery was 98-103 %. Serum 25(OH)D and 1,25(OH) 2 D concentrations were measured by radioimmunoassay (RIA; DiaSorin Inc., Stillwater, MN) [25] . The intra-assay CV for 25(OH)D and 1,25(OH) 2 D was 2.2 and 7-11 %, respectively [26] . Serum 24,25(OH) 2 D was measured using a combined liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for 24,25(OH) 2 D and 25(OH)D [23, 27] . The method has a lower limit of quantification (CV 20 %) of 0.5 ng/mL and inter-assay imprecision of 8.58 % at 1.5 ng/mL. This assay simultaneously generated measures of 25(OH)D. The RIA and LC-MS/MS measures of 25(OH)D were highly correlated among the 140 participants with both results (Spearman's rho=0.97, p<0.001). The data presented here are limited to the RIA results.
Intact PTH (iPTH) and bioactive PTH (1-84PTH) concentrations were measured by RIA with a CV of 3-5 % and 3-10 %, respectively (Scantibodies Clinical Laboratory, Santee, CA) [28] . Intact FGF23 was measured via ELISA (Kainos Laboratories Inc., Tokyo, Japan; CV 6.7-12.4 %). Serum albumin and creatinine were measured by spectrophotometric enzymatic assay (Vitros, Johnson & Johnson Co., Rochester, NY) with CVs of 1-2 and 1-5 %, respectively. Serum calcium and phosphorus were measured using standard clinical methods with CVs of 1.3 and ≤2.1 %, respectively; the calcium concentration was corrected for albumin [29] .
The eGFR, mL/min/1.73 m 2 ) was calculated based on height and serum creatinine using the estimating equation generated in the Chronic Kidney Disease in Children Study (CKiD) [30] . Participants were categorized into three groups according to CKD stage [31] Concentrations of albumin, DBP, and 25(OH)D in these equations are given in moles per liter, and free and bioavailable 25(OH)D were then converted to picograms per milliliter and nanograms per milliliter, respectively, for ease of interpretation of the results.
Disease characteristics and medications
Medical charts were reviewed for the date of diagnosis of CKD, underlying etiology of renal disease, dialysis history, and prior medications. Information on current medications and vitamin D intake from multivitamins and dietary supplements was obtained by questionnaire and review of the medical record.
Statistical analyses
All analyses were performed using STATA 11.0 (Stata Corp., College Station, TX). A two-sided p value of <0.05 was considered to be statistically significant. Distributions of all variables were assessed for normality. Descriptive statistics for continuous variables were reported as the mean ± standard deviation values for normally distributed data and for skewed data as the median and inter-quartile range (IQR). Group differences were assessed using Student's t, analysis of variance (ANOVA), Wilcoxon rank sum or Kruskal-Wallis tests as appropriate, and the nptrend command in STATA was used as the nonparametric test for trend across ordered groups. The chi-square test was used to assess differences in proportions. Skewed variables were natural log-transformed as previously described [34] . Serum 25(OH)D concentrations were categorized as deficient (<20 ng/mL) or not, in accordance with the 2011 Institute of Medicine report [35] . Analyses of the association between underlying renal disease and DBP concentrations were stratified by dialysis (CKD stages 2-5 vs. stage 5D), because participants on dialysis may have insufficient glomerular filtration to demonstrate disease-specific effects related to proteinuria and proximal tubular function. Correlations were assessed by the Pearson product moment or Spearman's rank correlations. The corcor program was used to test the equality of two dependent correlations.
Multivariable linear regression analysis was used to evaluate potential correlates of serum free and bioavailable 25(OH)D concentrations, including age, race (black race vs. others), sex, winter season (November-April vs. remaining months), study site, BMI Z-score, vitamin D supplementation (≥400 vs. <400 IU/day), calcitriol therapy, underlying diagnosis, CKD stage, and FGF23 concentrations. Variables were retained in the final models if the p value was <0.05. Model assumptions were assessed via graphical checks, for example, to assess linearity of relationships and the normality of residuals. 
Results
Participant characteristics
The median age of our cohort was 14.1 (IQR 11.1, 17.5) years. Of the 148 participants, 61 % were male, 25 % were black, and 32 % had glomerular disease. Nearly half of the study visits were conducted during the winter season. Participants were evenly distributed amongst CKD stages. While the use of calcitriol therapy was common, particularly in patients with advanced stage CKD, only 17 % of the cohort was receiving nutritional supplementation of at least 400 IU of vitamin D daily. Table 1 When limited to pre-dialysis participants, DBP concentrations were significantly lower in those with FSGS than in all other diagnoses (median 13.1 vs. 21.0 mg/dL, respectively; p = 0.01), and this difference persisted after 
Discussion
To our knowledge, this is the first study to assess free and bioavailable 25(OH)D, and 24,25(OH) 2 D concentrations and their determinants in pediatric CKD. Prior studies of free vitamin D concentrations in patients with renal disease are limited, but raised concerns regarding the interpretation of total concentrations in the setting of urinary losses of DBP and albumin. Proteinuria frequently complicates pediatric CKD; 75 % of participants in the CKiD cohort were proteinuric at baseline, 14 % of whom had nephrotic-range proteinuria [36] . Given the burden of proteinuria in childhood CKD, the assessment of free and protein-bound vitamin D concentrations is an important first step towards understanding the determinants and consequences of abnormal vitamin D metabolism in this population.
In our prior study of this cohort, we reported that glomerular disease, particularly FSGS, was an independent risk factor for 25(OH)D deficiency, compared with CAKUT [4] . We hypothesized that lower 25(OH)D concentrations in glomerular diseases were due to urinary losses of DBP. This subsequent study confirmed lower serum DBP concentrations in pre-dialysis participants with FSGS. However, total 25(OH)D was not associated with serum DBP, and glomerular diseases were associated with lower free and bioavailable 25(OH)D concentrations, suggesting that impaired vitamin D metabolism likely involves mechanisms extending beyond urinary losses of binding proteins. Further supporting this hypothesis is recent evidence that antiproteinuric therapy in CKD patients reduced urinary DBP loss, but did not impact serum DBP or vitamin D concentrations [37] . Our finding that FSGS was associated with significantly lower DBP concentrations among pre-dialysis CKD, but not dialysis participants, suggests that the underlying disease does not impact serum DBP in the absence of sufficient glomerular filtration and urine output. In a related study, Prytula et al. reported that serum DBP concentrations in ten children with CKD stage 4-5 were within the normal reference range [38] ; however, these authors did not assess the impact of the underlying disease and excluded patients with nephrotic syndrome. They also documented similar DBP concentrations in 16 children on peritoneal dialysis, despite dialysate losses of DBP. Similarly, we did not find lower serum DBP in the 16 participants on peritoneal dialysis compared to those on hemodialysis or those with CKD stage 4-5. [8] [9] [10] [11] . Vitamin D-DBP complexes are freely filtered by the glomerulus and reabsorbed, along with numerous other ligands, including PTH, via megalin/cubilin-mediated endocytosis in the proximal tubule. The conversion of 25(OH)D to 1,25(OH) 2 D by CYP27B1 depends on this process, [12, 13] , and animal studies have shown that blocking this reabsorptive pathway has far greater adverse effects on mineral metabolism and skeletal health than DBP deficiency [42, 43] . The contribution of proximal tubular dysfunction to disordered mineral metabolism in CKD has not been elucidated. The fact that FSGS was associated with lower 1,25(OH) 2 Bhan et al. [7] reported that bioavailable 25(OH)D was more tightly linked with measures of mineral metabolism (serum calcium and PTH) than total 25(OH)D, based on their findings in 94 incident adult dialysis patients. Calcium was not associated with total 25(OH)D (r=0.01, p=0.92), but was positively correlated with bioavailable 25(OH)D (r = 0.26, p = 0.01). Similarly, total 25(OH)D was not associated with PTH (β=−0.21, p=0.28) but bioavailable 25(OH)D was (β=−0.32, p=0.02). We did not corroborate these findings in our pediatric cohort. By contrast, total 25(OH)D was associated with serum calcium, while free and bioavailable 25(OH)D were not (although there was no statistically significant difference among the correlations), and iPTH was inversely and comparably associated with total, free, and bioavailable 25(OH)D (Spearman's rho of −0.48, −0.38 and −0.41, respectively). It must be noted that our two study populations differed considerably in terms of their distribution of age, CKD severity, and underlying disease.
The findings of our study corroborate recent findings of altered vitamin D catabolism in adults with CKD [23] . As in adults, more advanced CKD was strongly associated with lower 24,25(OH) 2 As reported in a recent adult study [23] , black race was associated with lower 24,25(OH) 2 D concentrations, independent of 25(OH)D, CKD severity, underlying diagnosis, iPTH, and FGF23. Together with the findings of lower DBP and comparable free 25(OH)D concentrations in black compared to non-black participants, this information emphasizes racial differences in vitamin D handling and catabolism that must be considered in the assessment of vitamin D status and which may render total 25(OH)D an incomplete index of sufficiency. The novel observation of higher 24,25(OH) 2 D in participants with GN, almost half of whom had systemic inflammatory disease, raises questions regarding the effect of inflammation on CYP24A1 activity [46] . This study has several limitations. First, the crosssectional design limits our ability to make causal inferences. Second, the under-representation of FSGS in the CKD stage 2/3 category limits the generalizability of our findings to patients with less advanced CKD or preserved renal function. Third, direct measures of free 25(OH)D are currently not commercially available; therefore, concentrations were estimated based on total 25(OH)D, DBP, and albumin concentrations. However, a recent study using these equations reported that bone density was associated with free (r=0.41, p=0.003) and bioavailable (r=0.44, p=0.002), but not total 25(OH)D (r = 0.18, p = 0.24) in healthy young adults, supporting the validity of these equations [32] . Furthermore, use of the equation developed by Bikle et al. yielded comparable results in our study and were highly correlated (r= 0.93) with free 25(OH)D measured by centrifugal ultrafiltration in prior studies [8] . Black patients may have a different distribution of DBP genotypes relative to non-black patients which may impact the affinity of DBP and hence the actual amount of bioavailable and free 25(OH)D. We do not have genotype data on this cohort, but future studies incorporating such genotype data and novel mathematical modeling of free 25(OH)D are needed [47] . Finally, as this analysis was an ancillary to an earlier bone study and urine collection was not a focus of the original study, we were limited by the lack of urine specimens and consequently by the lack of data on the magnitude of proteinuria and urinary DBP loss.
This study has important strengths. It is one of the largest studies of mineral metabolism in childhood CKD and the first to examine concentrations of DBP, free and bioavailable 25 [48, 49] . The heterogeneity of our study population enabled us to examine the impact of underlying disease on concentrations of vitamin D and its binding protein. Our pre-dialysis population was representative based on comparison to CKiD [36] .
In summary, we observed that among children and adolescents with CKD, glomerular disease, especially FSGS, was independently associated with lower free and bioavailable 25(OH)D concentrations. Pre-dialysis participants with FSGS also had lower 1,25(OH) 2 
